Cytomegalovirus Retinitis in a Patient Who Received Ruxolitinib
The Janus kinase 2 inhibitor ruxolitinib can produce defects in host defenses that may lead to opportunistic infections such as cytomegalovirus retinitis. To the Editor: A 67-year-old man received a diagnosis of primary myelofibrosis with extramedullary hematopoiesis and splenomegaly in 2009. In Dec...
Saved in:
Published in | The New England journal of medicine Vol. 374; no. 3; pp. 296 - 297 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
United States
Massachusetts Medical Society
21.01.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The Janus kinase 2 inhibitor ruxolitinib can produce defects in host defenses that may lead to opportunistic infections such as cytomegalovirus retinitis.
To the Editor:
A 67-year-old man received a diagnosis of primary myelofibrosis with extramedullary hematopoiesis and splenomegaly in 2009. In December 2013, treatment with ruxolitinib (Jakafi) was initiated at a dose of 15 mg twice daily. There was a palpable reduction in spleen size.
In June 2014, the patient presented to his ophthalmologist with unilateral anterior uveitis. Treatment was initiated with mydriatic eyedrops and a low-dose regimen of topical glucocorticoids. During follow-up, no response to this therapy was noted, and signs of posterior involvement had developed.
The patient was referred to our clinic, where a slight vitritis and a few . . . |
---|---|
ISSN: | 0028-4793 1533-4406 |
DOI: | 10.1056/NEJMc1413918 |